-
Insights from the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
DRG’s oncology experts help pharma companies solve their toughest business problems in drug development, product commercialization, market access, and portfolio strategy. With 20 dedicated oncology...
-
Likely Impact of Emerging GLP-1 Receptor Agonists on the European T2D Market
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s liraglutide and Eli Lilly’s dulaglutide, are among the most efficacious type 2 diabetes (T2D) therapies available in...
-
CAR T-Cell Therapy: The Drive to Market
Will 2017 be the debut year for CAR T-cell therapies? Likely ‘yes’! Following a crescendo of clinical advances (and setbacks) in 2016, in the first quarter of 2017, the race to market became...
-
The Fight to Launch Generics in Multiple Sclerosis: A Look at Recent Inter Partes Review Activity in This High-Cost, Blockbuster Market
Five disease-modifying therapies for the treatment of multiple sclerosis achieved blockbuster sales in the United States in 2016. As such, it is not surprising that generic manufacturers have...
-
Advancements in Gastroenterology: A Review of Digestive Disease Week 2017
With the global aging population, growing pervasiveness of Westernized diets, rising prevalence and incidence rates of obesity, Crohn’s disease, irritable bowel syndrome (IBS), and gastrointestinal...
-
The Lupus Nephritis Pipeline: A Shakespearean Tragedy?
The level of unmet need is high in the lupus nephritis market; despite developers’ past attempts to target this indication, no drug has been able to secure approval in the United States or Europe...
-
What the data has to show: Insights in Orthopaedics
Orthopaedic companies face unique challenges in the quest to stay competitive. From demands dictated by the shifting site of service to ASCS to the necessity of highly competitive pricing strategies...
-
Follow-on drugs: Circumventing the customary patent cliffs in Big Pharma
For decades, Pharma juggernauts have been facing the challenge of patent cliffs for their blockbuster drugs. In light of the intense competition offered by generics, Big Pharma is exploring a plethora...
-
Merck’s Verubecestat Fails in Mild to Moderate AD: What Now?
On February 14, 2017, Merck announced it was halting the Phase III EPOCH study of its BACE inhibitor verubecestat in mild to moderate Alzheimer’s disease (AD) due to lack of efficacy. In DRG’s...
A global consultancy and training agency providing market leading product & portfolio strategy, health economic outcomes research & evidence generation, value communication and training services across the life science industry.
We partner with both the biopharmaceutical and medical technology industry to support commercialization & patient access across a variety of functions including: R&D, commercial strategy, HEOR, market access, new product planning, marketing, data insights & analytics, business development and channel & segment customer engagement.
